AzTrials
AzTrials

Paraplegia, CompleteAPPEXNCT06941896

Effect of the Atalante Exoskeleton on Standing and Walking in Individuals With Paraplegia: A Prospective Controlled-Environment Study in a Rehabilitation Context

A study testing Use of the Atalante Exoskeleton in people with Paraplegia, Complete, run by Centre Hospitalier Universitaire de Nīmes at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This clinical study aims to evaluate the feasibility, safety, and acceptability of the Atalante robotic exoskeleton, developed by Wandercraft, within a functional rehabilitation protocol for individuals with complete paraplegia. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Paraplegia, Complete
What is being tested?
Use of the Atalante Exoskeleton
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
13 participants
Where
1 siteFrance
Study dates
Jan 2017to Sep 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Complete spinal cord injury (ASIA A classification)
  • Lesion level at or below T6
  • Injury occurred more than 6 months prior to enrollment (chronic/stabilized injury)
  • Ability to maintain upright posture without symptomatic orthostatic hypotension
  • Joint range of motion compatible with wearing the exoskeleton
  • Anthropometric dimensions compatible with the device, including:
  • Body weight less than 90 kg

Who cannot join

  • Spasticity greater than 3 on the Modified Ashworth Scale
  • Joint limitations incompatible with exoskeleton use
  • Spinal instability
  • Cognitive or psychiatric disorders affecting protocol adherence
  • Recent dermatological conditions
  • History of fragility fractures in the lower limbs within the past 2 years
Show all 14Show fewer
  • Presence of 5 or more fracture risk factors according to Craven et al., including:
  • Injury older than 10 years
  • Thoracic-level lesion
  • Absence of regular weight-bearing activity
  • Low spasticity
  • Body Mass Index (BMI) < 20
  • Cardiopulmonary contraindications to physical effort
  • Pregnancy or breastfeeding

Trial locations and contacts

1 site in 1 country.

France1 site
  • CMPR APAJH Pionsat

    Pionsat, Auvergne, 63330

Other trials in France

About this study

Official title: Study of the Effect of the Atalante Exoskeleton (Wandercraft) on Autonomy in Individuals With Paraplegia Undergoing Rehabilitation (Standing and Walking): A Prospective Uncontrolled Study in a Controlled Environment to Demonstrate Its Physical and Psychosocial Utility.

This clinical study aims to evaluate the feasibility, safety, and acceptability of the Atalante robotic exoskeleton, developed by Wandercraft, within a functional rehabilitation protocol for individuals with complete paraplegia. Unlike re-education, which focuses on restoring impaired functions, rehabilitation seeks to promote long-term autonomy despite persistent impairments.

The study would involve adult participants with complete spinal cord injury-induced paraplegia. Each participant would follow an intensive program of 60 sessions over six weeks, including phases of verticalization, postural stabilization, and assisted locomotion. The protocol would include three evaluation domains: (1) biomedical safety (orthostatic tolerance, adverse events, metabolic load), (2) techno-functional usability (setup time, technical incidents), and (3) user-perceived trust (comfort, sense of safety, satisfaction).

The primary objective would be to determine whether the Atalante exoskeleton can be safely and repeatedly used by individuals with complete paraplegia without requiring manual support. The study would also aim to identify potential barriers to its integration into an intensive rehabilitation protocol. The expected outcomes could guide clinical practices and help define optimal inclusion criteria for the safe and effective use of this technology.

Read the detailed description

Background and Rationale Complete paraplegia, resulting from spinal cord injury, is a major neurological condition involving irreversible loss of lower limb function. Given the limitations of neuromotor re-education in such contexts, rehabilitation aims to restore autonomy and social participation by leveraging residual capacities and assistive technologies. Robotic exoskeletons represent a promising technological innovation in this domain by offering assisted locomotion that compensates for loss of mobility.

Among these devices, Atalante (Wandercraft, Paris, France) is a next-generation, self-stabilizing exoskeleton designed to enable dynamic walking without manual support, through a fully motorized lower limb system. Unlike conventional devices that require crutches or canes, Atalante provides active stabilization, offering new perspectives in terms of autonomy, safety, comfort, and quality of life.

While the potential benefits of exoskeletons in motor recovery have been explored, their use in a functional rehabilitation context remains under-investigated. This project therefore aims to evaluate the Atalante exoskeleton as an assistive tool for autonomy within a structured intensive protocol in a safe clinical environment.

Primary Objective To evaluate the feasibility, safety, and acceptability of intensive use of the Atalante exoskeleton in a functional rehabilitation context among adults with chronic complete paraplegia.

Secondary Objectives To determine the number of sessions required to reach operational familiarization with the exoskeleton.

To describe technical incidents and their impact on comfort and perceived safety.

To assess the energy cost of assisted locomotion.

To identify potential bone contraindication criteria based on bone mineral density (T-score).

To measure the evolution of user satisfaction throughout the protocol.

Investigational Device: Atalante Exoskeleton

The Atalante exoskeleton is an active robotic system with 12 powered degrees of freedom symmetrically distributed across both lower limbs (3 at the hip, 1 at the knee, 2 at the ankle). It enables:

Biomimetic joint movements,

Active postural control,

Self-stabilized dynamic walking without external support.

Its hybrid control system (continuous/discrete time) is based on Hybrid Zero Dynamics algorithms, which optimize movement trajectories and ensure real-time dynamic balance. The user interface allows switching between multiple modes (sit-to-stand, walk, stop) via remote control. Inertial sensors, angular encoders, and pressure sensors detect the user's intention to move.

Study Design Type: Prospective, single-center, longitudinal, non-randomized study.

Intervention duration: 6 weeks (60 sessions per participant).

Location: Centre de Médecine Physique et Réadaptation APAJH, Pionsat (France).

Safety setup: Overhead rail system with active fall protection, non-interfering with device operation.

Population Participants will be adults with complete paraplegia (ASIA A), lesion level ≤ T6, with stabilized spinal cord injury. They must present anthropometric parameters compatible with the exoskeleton (height, weight, joint mobility). Selection will be based on strict eligibility criteria (see "Eligibility" section).

Intervention Protocol

Each participant will undergo:

2 sessions/day, 5 days/week for 6 weeks.

Each session includes:

Assisted verticalization (sit-to-stand),

Orthostatic stabilization (upright stance without support),

Assisted locomotion (stabilized walking).

Sessions will be supervised by trained professionals. A session will be considered valid if the participant completes a 40-meter round trip without incident. The intensity of the program is designed to simulate realistic sustained home use.

Evaluation Domains

  1. Biomedical Safety Monitoring of adverse events (major and minor): fractures, skin abrasions, orthostatic hypotension, pain. Metabolic analysis (VO₂, cost of transport, perceived exertion via Borg scale) during sessions 21 and 60. Exploratory contraindication: T-score < -3.5 at the hip (severe osteoporosis).
  2. Techno-Functional Usability Donning and doffing times (sessions 1 to 60), Number and type of technical incidents: unexpected stops, deviations, backward perturbations, software bugs. Functional familiarization assessment (Elbow Curve method).
  3. Perceived Confidence and Acceptability

Session-end assessments via:

Visual analog scales (VAS): general comfort, thoracic harness comfort, safety while standing, walking, and during transitions.

QUEST 2.0 questionnaire at the end of the protocol.

Data Analysis Methodology Quantitative data will be expressed as means ± standard deviation or medians (interquartile ranges).

Intra-subject pre/post comparisons: Student's t-test for parametric data, Wilcoxon test otherwise.

Longitudinal follow-up: progression curves for donning time, technical incidents, and VAS scores.

Effect size and significance thresholds: p < 0.05; 95% confidence intervals.

Ethics The study will be conducted in accordance with the principles of the Declaration of Helsinki. It has received approval from the Ethics Committee (CPP) and the French Medicines Agency (ANSM). All participants will sign informed consent. French CPP : 2016-A01221-50.

Expected Outcomes

The results of this study could:

Confirm the relevance of Atalante in a functional rehabilitation approach,

Provide practical recommendations for safe clinical use,

Prepare future multicenter studies in real-life environments (home, urban spaces),

Contribute to the development of eligibility criteria for prescribing exoskeletons as assistive mobility devices.

Being tested
Use of the Atalante Exoskeleton
Keywords
exoskeleton, Atalante, paraplegia, rehabilitation, safety
Medical subject headings
Paraplegia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Use of the Atalante ExoskeletonDevice

    Assisted verticalization (sit-to-stand transition)

    Orthostatic stabilization (unsupported standing posture)

    Assisted locomotion (stabilized walking)

Study groups in NCT06941896
Study groupRoleWhat they receive
Exosquelette AtalanteExperimentalNot described
Receives: Device: Use of the Atalante Exoskeleton

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Adverse events related to the use of the Atalante exoskeleton

    Evaluation of biomedical safety through systematic recording of adverse events (serious and non-serious) occurring during the training program, including but not limited to: fractures, dermabrasions, orthostatic hypotension, joint or muscle pain.

    Measured: At each session, through study completion (6 weeks total)

Secondary outcomes (10)
  1. Evolution of oxygen consumption during assisted locomotion

    Measurement of oxygen consumption (VO₂) during a 6-minute walk test using the Atalante exoskeleton. Results are expressed in mL O₂/kg/m.

    Measured: Session 21 (week 3) and session 60 (week 6)

  2. Evolution of transport cost during assisted locomotion

    Measurement of transport cost calculated from oxygen consumption data during a 6-minute walk test with the Atalante exoskeleton.

    Unitless or specify your formula (e.g., mL O₂/kg/m)

    Measured: Session 21 (week 3) and session 60 (week 6)

  3. Evolution of perceived exertion during assisted locomotion

    Assessment of perceived exertion using the Borg Rating of Perceived Exertion (RPE) scale after a 6-minute walk test with the Atalante exoskeleton. The Borg scale ranges from 0 (no exertion) to 10 (maximal exertion). Higher scores indicate greater perceived exertion. Units:

    Points on the Borg RPE scale (0-10)

    Measured: Session 21 (week 3) and session 60 (week 6)

  4. Perceived general comfort during use of the Atalante exoskeleton

    Evaluation of general comfort using a Visual Analog Scale (VAS) during sit-to-stand, standing, and walking with the Atalante exoskeleton. The VAS ranges from 0 mm (no discomfort) to 100 mm (maximal discomfort). Lower scores indicate better comfort.

    Units: mm on VAS (0-100 mm)

    Measured: At each session, through study completion (6 weeks total)

  5. Perceived thoracic comfort during use of the Atalante exoskeleton

    Evaluation of thoracic comfort using a Visual Analog Scale (VAS) during sit-to-stand, standing, and walking with the Atalante exoskeleton. The VAS ranges from 0 mm (no discomfort) to 100 mm (maximal discomfort). Lower scores indicate better thoracic comfort.

    Units: mm on VAS (0-100 mm)

    Measured: At each session, through study completion (6 weeks total)

  6. Perceived feeling of safety during use of the Atalante exoskeleton

    Evaluation of participants' perceived safety using a Visual Analog Scale (VAS) during sit-to-stand, standing, and walking with the Atalante exoskeleton. The VAS ranges from 0 mm (no feeling of safety) to 100 mm (maximal feeling of safety). Higher scores indicate greater perceived safety.

    Units: mm on VAS (0-100 mm)

    Measured: At each session, through study completion (6 weeks total)

  7. Participant satisfaction with the Atalante exoskeleton assessed by the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0) scale

    Evaluation of overall satisfaction with the Atalante exoskeleton using the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0) scale. This standardized questionnaire includes 8 items rated from 1 (not satisfied at all) to 5 (very satisfied), assessing comfort, safety, ease of use, durability, effectiveness, aesthetics, and adjustability. Higher scores indicate greater satisfaction. Units:

    Points on QUEST 2.0 scale (1-5 per item; total score range: 8-40)

    Measured: At study completion (week 6)

  8. Change in donning and doffing time for the exoskeleton

    Measurement (in seconds) of time required to put on and remove the exoskeleton at each session. Analysis of progression in technical handling over time.

    Measured: At each session, through study completion (6 weeks total)

  9. Frequency and types of technical incidents

    Systematic recording of technical incidents (minor and major), including unexpected shutdowns, software errors, trajectory deviations, and other anomalies. Data correlated with participant perception of safety and session interruptions.

    Measured: At each session, through study completion (6 weeks total)

  10. Number of sessions required for functional familiarization with the exoskeleton

    Estimation of the number of training sessions needed for each participant to reach a performance plateau in donning and doffing the Atalante exoskeleton. The plateau is defined via curve inflection analysis using the Elbow Method. Units: Number of sessions

    Measured: Through study completion (up to 6 weeks)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Apr 2025
  2. Study startJan 2017
  3. Primary completionSep 2019
  4. Study completionSep 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
All participants will receive the same intervention: the use of the Atalante exoskeleton for assisted standing and walking during rehabilitation. There is no control group.
Masking
None (open label)
Enrolment
13 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06941896
Sponsor's protocol ID
2016-A01221-50
Acronym
APPEX
Status last verified
Apr 2025
First submitted
1 Apr 2025
Last updated
24 Apr 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: The sharing of individual participant data is not planned at this stage due to the exploratory nature of the study and the limited sample size. However, anonymized data could be made available upon a justified request, subject to approval by the ethics committee and the sponsor, within the framework of a scientific collaboration or future meta-analyses

Publications

  • Pantera E, Reneaud N, Bouscavert C, Pradon D. A multidimensional evaluation of the Atalante exoskeleton as an assistive locomotion device for individuals with complete paraplegia: a prospective longitudinal study in a controlled environment. J Neuroeng Rehabil. 2026 Jun 24. doi: 10.1186/s12984-026-01966-z. Online ahead of print.

    PubMed 42343362

Questions about this trial

What is this clinical trial studying?

A study testing Use of the Atalante Exoskeleton in people with Paraplegia, Complete, run by Centre Hospitalier Universitaire de Nīmes at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Adverse events related to the use of the Atalante exoskeleton (time frame: At each session, through study completion (6 weeks total)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06941896, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in